India

Vopec Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna

Lead Product(s): Amrta Karuna

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

Notable results for the Amrta Karuna treatment group compared to the control showed Significant reduction in hospital quarantine (28% decrease) , Significantly reduced CRP inflammatory levels, RT-PCR negative on day 7 at 71.42% vs 42.85% , TLC within normal range.

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu®

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: FabiFlu

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2020

Details:

Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team within the country, ensuring self-reliance with regard to longterm production and manufacturing.

Pankajakasthuri Herbal Research Foundation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pankajakasthuri Announces Promising Interim Results for ZingiVir–H Among COVID-19 Patients

Lead Product(s): Zingivir-H

Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H

Highest Development Status: Phase IV Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 10, 2020

Details:

Clinical trials of ZingiVir-H, Pankajakasthuri’s new drug, are underway among 112 patients as an adjunct therapy for the pandemic as well as among 135 additional patients as a stand-alone treatment in a double-blind study.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Vopec Pharmaceuticals

Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna

Glenmark

Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu®

Pankajakasthuri Herbal Research Foundation

Pankajakasthuri Announces Promising Interim Results for ZingiVir–H Among COVID-19 Patients